REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi

Regenxbio Inc. (RGNX) PT Lowered to $127.50 at Chardan Capital Markets; Sees Low Bar in Wet AMD

August 8, 2018 12:20 PM EDT

Chardan Capital Markets lowered its price target on Regenxbio Inc. (NASDAQ: RGNX) to $127.50 (from $130.00) while maintaining a Buy rating following positive interim data from its phase I study of RGX-314 in wet AMD (NCT03066258) and to us negative interim data in... More

Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD

August 8, 2018 7:44 AM EDT

Regenxbio (NASDAQ: RGNX) reported Q2 EPS of $0.30, $0.93 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $40.03 million versus the consensus estimate of $100 million.

"We are very encouraged by the positive interim data for RGX-314 and the potential of NAV gene therapy as a one-time treatment for wet AMD,... More